Alerts
COVID-19 update
See our updated visitor policy, which now allows 1 visitor per patient during exams only. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

Randomized, Double-Blind, Phase III Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine T-DM1 For Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03975647

Study #:
STUDY00144411

Start Date:
Apr 08, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03975647

View Complete Trial Details & Eligibility at ClinicalTrials.gov